This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Ferring Pharmaceuticals Ltd

Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
Telephone: +44 (0)844 931 0050
Fax: +44 (0)844 931 0051
WWW: http://www.ferring.co.uk
Medical Information e-mail: medical@ferring.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 25/07/2012
SPC DesmoMelt 120mcg and 240mcg oral lyophilisate


Go to top of the page
1. Name of the medicinal product

DesmoMelt 120 micrograms oral lyophilisate

DesmoMelt 240 micrograms oral lyophilisate


Go to top of the page
2. Qualitative and quantitative composition

Each unit contains 120 or 240 micrograms desmopressin (as acetate).

For excipients, see 6.1


Go to top of the page
3. Pharmaceutical form

Oral lyophilisate

DesmoMelt 120 micrograms oral lyophilisate

White, round, oral lyophilisate marked with two drop shaped figures on one side.

DesmoMelt* 240 micrograms oral lyophilisate

White, round, oral lyophilisate marked with three drop shaped figures on one side.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

DesmoMelt is indicated for the treatment of primary nocturnal enuresis.


Go to top of the page
4.2 Posology and method of administration

DesmoMelt is for sublingual use.

Children (from 5 years of age) and adults (up to 65 years of age) with normal urine concentrating ability who have primary nocturnal enuresis should take 120 micrograms at bedtime administered sublingually and only if needed should the dose be increased to 240 micrograms sublingually.

The need for continued treatment should be reassessed after 3 months by means of a period of at least 1 week without DesmoMelt.


Go to top of the page
4.3 Contraindications

DesmoMelt is contraindicated in cases of cardiac insufficiency and other conditions requiring treatment with diuretic agents. DesmoMelt should only be used in patients with normal blood pressure.

Before prescribing DesmoMelt, the diagnoses of psychogenic polydipsia and alcohol abuse should be excluded.

Desmopressin should not be prescribed to patients over the age of 65 for the treatment of primary nocturnal enuresis.


Go to top of the page
4.4 Special warnings and precautions for use

Care should be taken with patients who have reduced renal function and/or cardiovascular disease or cystic fibrosis. In chronic renal disease the antidiuretic effect of DesmoMelt would be less than normal.

When DesmoMelt is used for the treatment of enuresis, fluid intake must be limited from 1 hour before until 8 hours after administration.

Patients being treated for primary nocturnal enuresis should be warned to avoid ingesting water while swimming and to discontinue DesmoMelt during an episode of vomiting and/or diarrhoea until their fluid balance is once again normal.

Precautions to prevent fluid overload must be taken in:

- conditions characterised by fluid and/or electrolyte imbalance

- patients at risk for increased intracranial pressure


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Substances which are known to induce SIADH e.g. tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine and carbamazepine, may cause an additive antidiuretic effect leading to an increased risk of water retention and/or hyponatraemia.

NSAIDs may induce water retention and/or hyponatraemia.

Concomitant treatment with loperamide may result in a 3-fold increase of desmopressin plasma concentrations, which may lead to an increased risk of water retention and/or hyponatraemia. Although not investigated, other drugs slowing intestinal transport might have the same effect.

A standardised 27% fat meal significantly decreased the absorption (rate and extent) of a 0.4mg dose of oral desmopressin tablets. Although it did not significantly affect the pharmacodynamic effect (urine production and osmolality) there is the potential for this to occur at lower doses. If a diminution of effect is noted, then the effect of food should be considered before increasing the dose.


Go to top of the page
4.6. Pregnancy and lactation

Pregnancy:

Data on a limited number (n=53) of exposed pregnancies in women with diabetes insipidus indicate rare cases of malformations in children treated during pregnancy. To date, no other relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development.

Caution should be exercised when prescribing to pregnant women. Blood pressure monitoring is recommended due to the increased risk of pre-eclampsia.

Lactation:

Results from analyses of milk from nursing mothers receiving high dose desmopressin (300 micrograms intranasally) indicate that the amounts of desmopressin that may be transferred to the child are considerably less than the amounts required to influence diuresis.


Go to top of the page
4.7 Effects on ability to drive and use machines

None


Go to top of the page
4.8 Undesirable effects

Side-effects include headache, stomach pain and nausea. Isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. Very rare cases of emotional disorders including aggression in children have been reported. Treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions.


Go to top of the page
4.9 Overdose

An overdose of DesmoMelt leads to a prolonged duration of action with an increased risk of water retention and/or hyponatraemia.

Treatment:

Although the treatment of hyponatraemia should be individualised, the following general recommendations can be given. Hyponatraemia is treated by discontinuing the desmopressin treatment, fluid restriction and symptomatic treatment if needed.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: vasopressin and analogues

ATC code: H01B A02

In its main biological effects, desmopressin does not differ qualitatively from vasopressin. However, desmopressin is characterised by a high antidiuretic activity whereas the uterotonic and vasopressor actions are extremely low.


Go to top of the page
5.2 Pharmacokinetic properties

The overall mean systemic bioavailability of desmopressin administered sublingually as Melts at doses of 200, 400 and 800 micrograms is 0.25% with a 95% confidence interval of 0.21% - 0.31%. The Cmax was 14, 30 and 65pg/ml after administration of 200, 400 and 800 micrograms respectively. tmax was observed at 0.5 – 2.0 hours after dosing. The geometric mean terminal half-life is 2.8 (CV= 24%) hours.

Correlation table between desmopressin in Tablet and Melt forms:

Tablet

Tablet

Melt

Melt

Desmopressin acetate

Desmopressin free base

Desmopressin free base

Desmopressin acetate

0.1mg

89 micrograms

60 micrograms

Approx. 67 micrograms *

0.2mg

178 micrograms

120 micrograms

Approx. 135 micrograms *

0.4mg

356 micrograms

240 micrograms

Approx. 270 micrograms *

*calculated for comparative purposes

The distribution volume of desmopressin after intravenous administration is 33 L (0.41 L/kg). Desmopressin does not cross the blood-brain barrier. Desmopressin exhibits a moderate to high variability in bioavailability, both within and between subjects. Concomitant use of food decreases the rate and extent of absorption by 40%.

In vitro, in human liver microsome preparations, it has been shown that no significant amount of desmopressin is metabolised in the liver and thus human liver metabolism in vivo is not likely to occur.

It is unlikely that desmopressin will interact with drugs affecting hepatic metabolism, since desmopressin has been shown not to undergo significant liver metabolism in in vitro studies with human microsomes. However, formal in vivo interaction studies have not been performed.


Go to top of the page
5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Gelatin

Mannitol

Citric acid, anhydrous


Go to top of the page
6.2 Incompatibilities

Not applicable


Go to top of the page
6.3 Shelf life

48 months


Go to top of the page
6.4 Special precautions for storage

Store in the original package in order to protect from moisture and light


Go to top of the page
6.5 Nature and contents of container

PVC/Polyamide/Aluminium/Polyamide/PVC blisters. Top foil consists of Paper/Polyester teraphthalate/Aluminium/heat seal lacquer. Strips of 10 oral lyophilisates in packs of 30 oral lyophilisates.


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
Administrative data

Go to top of the page
7. Marketing authorisation holder

Ferring Pharmaceuticals Ltd.

Drayton Hall

Church Road

West Drayton

UB7 7PS

United Kingdom


Go to top of the page
8. Marketing authorisation number(s)

DesmoMelt 120 micrograms oral lyophilisate PL 03194/0094

DesmoMelt 240 micrograms oral lyophilisate PL 03194/0095


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

19th January 2006


Go to top of the page
10. Date of revision of the text

June 2011



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/17268/SPC/


Active Ingredients/Generics